Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4430 | collection of mucosal lining fluid Wiki | 1.00 |
| drug1793 | Hydroxychloroquine Pre-Exposure Prophylaxis Wiki | 1.00 |
| drug4400 | blood collection via fingerprick Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In this study nasal fluid (mucosal lining fluid), nose and throat swabs and blood was collected from patients with a confirmed SARS-CoV-2 infection who remained in home isolation, as well as from their household contacts who remained in home quarantine. On the collected nose and throat swabs a coronavirus PCR was performed. Antibodies against SARS-CoV-2 were measured in the mucosal lining fluid and blood samples.
Description: Descriptive analysis of SARS-CoV-2 IgG, IgM and IgA concentrations in nasal fluid
Measure: Mucosal antibodies Time: Day 0Description: Descriptive analysis of SARS-CoV-2 IgG, IgM and IgA concentrations in nasal fluid
Measure: Mucosal antibodies Time: Day 3 (index cases)Description: Descriptive analysis of SARS-CoV-2 IgG, IgM and IgA concentrations in nasal fluid
Measure: Mucosal antibodies Time: Day 6 (index cases)Description: Descriptive analysis of SARS-CoV-2 IgG, IgM and IgA concentrations in nasal fluid
Measure: Mucosal antibodies Time: Day 7 (household contacts)Description: Descriptive analysis of SARS-CoV-2 IgG, IgM and IgA concentrations in nasal fluid
Measure: Mucosal antibodies Time: Day 14 (household contacts)Description: Descriptive analysis of SARS-CoV-2 IgG, IgM and IgA concentrations in nasal fluid
Measure: Mucosal antibodies in all participants Time: Day 28Description: SARS-CoV-2 PCR on nasopharyngeal swab and throat swab
Measure: SARS-CoV-2 infection Time: day 0Description: Descriptive analysis of SARS-CoV-2 antibody concentrations in serum at day 28.
Measure: Serum antibodies Time: day 28Description: Descriptive analysis of the functionality of SARS-CoV-2 mucosal and serum antibodies
Measure: Functional antibody assays Time: Day 0Description: Descriptive analysis of the functionality of SARS-CoV-2 mucosal and serum antibodies
Measure: Functional antibody assays Time: Day 3 (index cases)Description: Descriptive analysis of the functionality of SARS-CoV-2 mucosal and serum antibodies
Measure: Functional antibody assays Time: Day 6 (index cases)Description: Descriptive analysis of the functionality of SARS-CoV-2 mucosal and serum antibodies
Measure: Functional antibody assays Time: Day 7 (household contacts)Description: Descriptive analysis of the functionality of SARS-CoV-2 mucosal and serum antibodies
Measure: Functional antibody assays Time: Day 14 (household contacts)Description: Descriptive analysis of the functionality of SARS-CoV-2 mucosal and serum antibodies
Measure: Functional antibody assays Time: Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports